▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #458 by analyst upside · 2026-06-27
BCYC
Bicycle Therapeutics plc
Healthcare · Market Cap $286M · P/E 0x
ANALYST PRICE TARGET
+207.9%
implied upside to consensus target
Current Price $4.1
Consensus Target $12.62
Bull Target $36.0
Bear Target $5.0
Analysts Covering 8
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
4
Hold
3
Sell
0
52-Week Low $3.92
52-Week High $9.18
YTD Return -38.6%
FUNDAMENTALS
Market Cap $286M
P/E Ratio (TTM) N/A
Forward P/E -1.9x
EPS (TTM) $-3.15
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $63M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.92
52-Week High $9.18
Current Price $4.1
Bear Target $5.0
Bull Target $36.0
● Now $4.1 ● Target $12.62
TRADING DATA
Avg Volume 449K
YTD Return -38.6%
Analyst Count 8
Consensus Buy
Upside to Target +207.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Bicycle Therapeutics plc (BCYC) is currently trading at $4.1 with a Wall Street consensus price target of $12.62, implying potential upside of 207.9% over the next 12 months. 8 analysts currently cover BCYC, with a consensus rating of Buy — 62% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $36.0, while the most cautious has a target of $5.0.

BCYC operates in the Healthcare sector with a market capitalisation of $286M. The stock is down 38.6% year-to-date and is currently trading near the lower end of its 52-week range of $3.92 – $9.18.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ABEO +251.4%
Abeona Therapeutics Inc.
$320M · P/E 5.9x · Buy
NAGE +268.4%
Niagen Bioscience, Inc.
$272M · P/E 16.3x · Buy
CGEN +120.1%
Compugen Ltd.
$198M · P/E 5.4x · Buy
CCLD +184.9%
CareCloud, Inc.
$91M · P/E 16.5x · Buy
OPRX +142.2%
OptimizeRx Corporation
$96M · P/E 13.5x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for BCYC, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2026-04-08 Building track record
Oppenheimer — Reiterated
Outperform → Outperform 2026-03-18 14% win rate (7 calls)
RBC Capital — Reiterated
Sector Perform → Sector Perform 2026-03-18 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-03-18 Building track record
Needham — Reiterated
Buy → Buy 2026-03-18 20% win rate (5 calls)
Truist Securities ● Initiated
Hold 2025-11-24 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2025-10-31 Building track record
RBC Capital ↓ Downgrade
Outperform → Sector Perform 2025-10-31 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →